PureTech Health News
Press releases
Press releases 2018-04-16
PureTech Health Announces Annual Results for Year Ended 31 December 2017
Press releases 2018-04-10
PureTech Health Affiliates Expand Digital Medicine IP Portfolios with Key Patent Issuances

US and international patent grants for Akili and Sonde technology platforms highlight PureTech’s foundational leadership position in the growing field of digital medicine

PureTech Health plc (LSE: PRTC) (“PureTech Health”), an advanced, clinical-stage biopharmaceutical company, announced today that its affiliates, Akili Interactive Labs, Inc. and Sonde Health, Inc., have been granted key patents broadly covering their respective proprietary technology platforms.

Continue
Press releases 2018-04-09
Microbiome-Derived Immune Modulators (Pediatric)
PureTech’s Commense Appoints President and Chief Executive Officer

Biotechnology veteran brings strong track record of strategic business development

PureTech Health plc (LSE: PRTC) (“PureTech Health”), an advanced, clinical-stage biopharmaceutical company, announced today the appointment of Edward J. “Tad” Stewart as President and Chief Executive Officer of its affiliate, Commense.

Continue
Press releases 2018-04-04
Inflammation-Targeting Technology
PureTech’s Alivio Technology Published in Nature Communications

Study demonstrates application of inflammation-responsive technology platform for the treatment of inflammatory diseases

PureTech Health plc (LSE: PRTC) (“PureTech Health”), an advanced, clinical-stage biopharmaceutical company, announced today that a preclinical study of the Alivio inflammation-responsive technology has been published in one of the leading scientific journals, Nature Communications.

Continue
Press releases 2018-02-01
GI Modulating Tunable Hydrogel
PureTech’s Gelesis Raises $30 Million to Prepare for Potential Launch of Lead Product

Proceeds to be used for manufacturing and commercialisation preparations and advancement of the Company’s clinical development pipeline

PureTech Health plc (LSE: PRTC) (“PureTech Health”), an advanced, clinical-stage biopharmaceutical company, announced today that Gelesis, an affiliate of PureTech Health, has successfully completed a $30 million financing round.

Continue
Press releases 2018-01-31
Selective mTORC1 Inhibitors
PureTech Affiliate resTORbio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Continue
Press releases 2018-01-26
Selective mTORC1 Inhibitors
PureTech Affiliate resTORbio Announces Pricing of Initial Public Offering and Approval to List on Nasdaq
Continue
Press releases 2018-01-03
Selective mTORC1 Inhibitors
PureTech Health Affiliate resTORbio Adds Lynne Sullivan, Biogen Senior Vice President, to Board of Directors

PureTech Health plc (LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that resTORbio, an affiliate of PureTech Health, today announced that Lynne Sullivan, Senior Vice President of Finance for Biogen, Inc., has joined the resTORbio board of directors as an independent director.

Continue
Press releases 2018-01-02
Selective mTORC1 Inhibitors
PureTech Health Affiliate resTORbio Files Public Registration Statement for Proposed Initial Public Offering

PureTech Health plc (LSE: PRTC) announced that resTORbio, Inc., an affiliate of PureTech Health, has filed a public registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock.

Continue
Press releases 2017-12-19
Oral Administration of Biologics – Novel Hydrogel
PureTech’s Entrega To Receive $5 Million Investment from Lilly To Advance Proprietary Oral Delivery Technology for Peptides

PureTech Health plc (LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that Entrega, an affiliate of PureTech Health, today announced a research collaboration with Eli Lilly and Company (NYSE: LLY) (“Lilly”).

Continue

@PureTechH